Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds Post published:July 21, 2021 Post category:Press Release
Mydecine Innovations Group Announces Launch of Mindleap Version 2.0 Post published:July 13, 2021 Post category:Press Release
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004 Post published:June 24, 2021 Post category:Press Release
Mydecine Unveils Artificial Intelligence Drug Discovery Program Post published:June 16, 2021 Post category:Press Release
Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms Post published:June 8, 2021 Post category:Press Release
Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms Post published:May 25, 2021 Post category:Press Release
Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets Post published:May 19, 2021 Post category:Press Release
Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update Post published:May 18, 2021 Post category:Press Release
Mydecine Announces Partnership with LeadGen Labs Post published:May 5, 2021 Post category:Press Release
Mydecine Reports Full Year 2020 Financial Results and Provides Business Update Post published:May 3, 2021 Post category:Press Release